The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van den Berg, R. H.
Right arrow Articles by Daha, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van den Berg, R. H.
Right arrow Articles by Daha, M. R.
The Journal of Immunology, 1998, 161: 6924-6930.
Copyright © 1998 by The American Association of Immunologists

The First Subcomponent of Complement, C1q, Triggers the Production of IL-8, IL-6, and Monocyte Chemoattractant Peptide-1 by Human Umbilical Vein Endothelial Cells1

Rocco H. van den Berg*, Maria C. Faber-Krol*, Robert B. Sim{dagger} and Mohamed R. Daha2,*

* Department of Nephrology, Leiden University Hospital, Leiden, The Netherlands; and {dagger} Medical Research Council Immunochemistry Unit, Department of Biochemistry, Oxford University, Oxford, United Kingdom


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We and others have demonstrated previously the occurrence of cC1qR/CaR, a receptor for the collagen-like stalks of complement component C1q, on endothelial cells. In the present study we investigated whether binding of C1q to endothelial cells resulted in enhancement of cytokine or chemokine production. HUVEC produced 82 ± 91 pg/ml of IL-8, 79 ± 113 pg/ml of IL-6, and 503 ± 221 pg/ml of monocyte chemoattractant peptide-1 (MCP-1) under basal conditions. Incubation with C1q resulted in a time- and dose-dependent up-regulation of IL-8 (1012 ± 43 pg/ml), IL-6 (392 ± 20 pg/ml), and MCP-1 (2450 ± 101 pg/ml). This production is dependent on de novo protein synthesis, as demonstrated by the detection of specific mRNA after C1q stimulation, and inhibition of peptide production in the presence of cycloheximide. The production of all factors was inhibited (69 ± 7%) by the collagenous fragments of C1q, while the C1q globular heads only induced 13 ± 11% inhibition. When HUVEC were incubated with C1q in the presence of aggregated IgM, enhanced production of IL-8 (2500 ± 422 pg/ml), IL-6 (997 ± 21 pg/ml), and MCP-1 (5343 ± 302 pg/ml) was found. Furthermore, F(ab')2 anti-calreticulin partially inhibited the production of IL-8, confirming at least the involvement of cC1qR/CaR. These experiments suggest that in an inflammatory response C1q not only is able to activate the complement pathway, but when presented in a proper fashion also might induce the production of factors that contribute to acute phase responses and recruitment of inflammatory cells.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
We described previously that C1q containing immune complexes bind to endothelial cells (EC)3 via a specific receptor for C1q (C1qR). Next to EC (1, 2, 3), C1q has also been shown to interact with a large number of other cell types, such as fibroblasts (4), epithelial cells (5), platelets (6), B cells (7), eosinophils (8), neutrophils (9), and monocytes (9). Binding of C1q to C1q receptors on these different cell types elicits differential cellular responses: for example, enhancement of phagocytosis by macrophages (10, 11, 12), enhanced secretion of Igs by B cells (13), and stimulation of the oxidative metabolism in neutrophils (14). To our knowledge, the effect of C1q binding to endothelium is limited to only two reports describing the enhanced binding to and phagocytosis of Salmonella minnesota (15) and up-regulation of ELAM, ICAM-1, and VCAM-1 (16). Since the initial demonstration of the binding of C1q to EC, three specific receptors for C1q have been described: a receptor for the globular domain of C1q (gC1qR) (17, 18), a receptor for the collagen-like stalks of C1q that has high homology with calreticulin (cC1qR/CaR) (3, 6, 16, 19, 20, 21, 22), and a receptor that enhances phagocytosis by monocytes (C1qRp) (23) (16, 24, 25). While others have suggested that gC1qR is present on the membrane of various cells (17), increasing evidence strongly suggests that gC1qR is a mitochondrial protein (26, 27, 28). The other two receptors, namely cC1qR/CaR and C1qRp, both have been shown to be present on the membrane of EC in vitro.

For host defense, EC are indispensable because they are involved in binding and phagocytosis of pathogens, attraction of inflammatory cells, activation of the coagulant system and the complement system, and local increment of blood vessel permeability. Most of these effects are mediated and regulated by cytokines, chemokines, and adhesion molecules.

Stimulation of EC with IL-1 and TNF, for example, results in direct (ICAM-1, ELAM, VCAM-1) and indirect (via IL-6) up-regulation of adhesion molecules, but will also induce the production of molecules such as RANTES, IL-8, and MCP-1, that are able to attract lymphocytes, neutrophils, and monocytes to the site of inflammation.

In the present study we investigated the ability of EC to produce cytokines and chemokines in response to C1q stimulation. These factors are of importance because they are involved in the attraction of neutrophils and monocytes/lymphocytes (IL-8, MCP-1) to the site of an inflammation.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Isolation of C1q and C1q fragments

C1q was isolated from human serum as previously described (29) with some modifications. C1q was precipitated from normal human serum with polyethylene glycol 6000 (3%, w/v) and dissolved in veronal-buffered saline. After adjustment of the conductivity to 12 mS, EDTA was added to a final concentration of 2 mM. The C1q-containing solution was applied to a human IgG Sepharose column that was incubated overnight with excess rabbit anti-human IgG. After extensive washing with PBS containing 2 mM EDTA, C1q was eluted with the same buffer now containing 1 M NaCl. C1q activity in the fractions was measured by a hemolytic assay (30); positive fractions were pooled, concentrated, and filtered on a Superdex 200 gel filtration column. Finally, to remove contaminating IgG, C1q-containing fractions were pooled and subsequently applied to a protein G column (Pharmacia, Roosendaal, The Netherlands). Again, C1q-containing fractions were pooled and stored on ice until use. The purified C1q was hemolytically active (30) and was shown to be devoid of contaminants as judged by SDS-PAGE (31). Also, approximately 8% of the C1q in the C1q preparation was shown to exist as aggregates (31).

Collagen-like stalks of C1q were prepared by pepsin digestion as described previously (31, 32). To remove noncleaved C1q, the isolated protein was applied to a human IgG Bio-Gel A5 column (Bio-Rad, Richmond, Ca). The fallthrough fractions containing the C1q stalks were then freeze-dried and stored in PBS containing 1% glycerol on ice. With a C1q hemolytic assay, no residual hemolytic activity could be detected.

C1q globular heads were prepared by collagenase treatment as described previously (33). Digested C1q was filtered on a TSK 3000 SW gel filtration column (Pharmacia, Uppsala, Sweden); the peak, which had an apparent molecular mass of 30 kDa and was reactive with polyclonal anti-C1q Abs, was pooled, concentrated, and analyzed on SDS-PAGE. This preparation of globular heads of C1q was devoid of residual C1q hemolytic activity.

Isolation and culture of HUVEC

EC were isolated by collagenase digestion of human umbilical cords (34) and were then cultured on gelatin-coated tissue flasks (Greiner, Alphen a/d Rijn, The Netherlands) in medium 199 containing 10% heat-inactivated FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, Earle’s salts (Sigma, St. Louis, MO), 7.5 U/ml heparin (Organon Technika, Boxtel, The Netherlands), and 0.002% (w/v) endothelial growth factor isolated from bovine hypothalamus as previously described (35). Cells were detached by trypsin and were used for the experiment between the fifth and seventh passages.

Stimulation of HUVEC with different doses of C1q

Confluent layers of EC in 24-well plates (Costar, Cambridge, MA) were rendered quiescent by overnight culture in medium 199 containing 0.5% FCS (36). After rinsing with PBS, the cells were incubated for 48 h in medium 199 containing 0.5% FCS with concentrations of C1q ranging from 0–250 µg/ml or with identical concentrations of BSA as a control. After incubation, supernatants were removed and assayed for IL-6, IL-8, and MCP-1 by ELISAs (see below). As a control, the concentration of complement factor H in the supernatants was also measured by ELISA.

Stimulation of HUVEC with C1q for different time periods

Quiescent HUVEC were incubated with 100 µg/ml C1q or BSA in medium 199 containing 0.5% FCS for different time periods, ranging from 0–48 h. Supernatants were obtained, and the concentrations of IL-6, IL-8, and MCP-1 were measured by ELISA.

Stimulation of HUVEC by C1q in the presence of C1q fragments

To determine the role of either the globular domain or the collagen-like stalks of C1q, quiescent HUVEC were incubated for 48 h with 50 µg/ml intact C1q in the presence of 50 µg/ml C1q globular heads, C1q collagen-like stalks, or BSA in medium 199 containing 0.5% FCS. The concentrations of IL-6, IL-8, and MCP-1 in the supernatants were determined by ELISA.

Cross-linking of HUVEC-bound C1q by aggregated rabbit IgM (AIgM)

Confluent quiescent layers of HUVEC were incubated with 50 µg/ml C1q or BSA for 1 h at 4°C, washed, and then incubated with increasing concentrations (0–80 µg/ml) of AIgM. AIgM was obtained by precipitation of serum from patients with Walden-Strom’s disease using boric acid, followed by filtration on Bio-Gel A5 (37). To obtain AIgM, IgM was subsequently incubated for 20 min at 63°C, and the supernatant containing AIgM was obtained by centrifugation. After 48-h incubation of HUVEC with C1q and AIgM, supernatants were tested in ELISA for IL-6, IL-8, and MCP-1 concentrations. All incubations were performed in medium 199 containing 0.5% FCS.

Effect of cycloheximide on C1q-mediated production of IL-8, IL-6, and MCP-1 by HUVEC

Quiescent HUVEC were preincubated for 4 h with either medium alone (medium 199 containing 0.5% FCS) or medium containing 10 µg/ml cycloheximide (Sigma), washed, and then stimulated with medium containing 100 µg/ml C1q or BSA in the presence of 10 µg/ml cycloheximide. After 48 h of incubation, the supernatants were harvested, and the concentrations of IL-6, IL-8, and MCP-1 were determined by ELISA. As a control, the concentration of factor H was also assessed.

Effect of F(ab')2 anti-calreticulin on C1q-induced IL-8, IL-6, and MCP-1 production by HUVEC

For the preparation of F(ab')2 anti-calreticulin (CaR) fragments, a polyclonal anti-CaR was used (provided by Dr. R. B. Sim, Oxford University, Oxford, U.K.), the specificity of which for CaR was previously established by Malhotra et al. (19) using Western blot analysis and RIAs with lymphocyte cC1qR/CaR. Furthermore, the Ab was shown to be able to bind to cC1qR/CaR on the cell surface of epithelial cells (38) and neutrophils (39).

The IgG fractions were prepared by ammonium precipitation, followed by anion exchange chromatography on DEAE-A50 Sephadex. F(ab')2 anti-CaR, and F(ab')2 anti-SRBC were obtained after pepsin digestion of, respectively, rabbit IgG anti-CaR (19) and rabbit IgG anti-SRBC (prepared in our laboratory) as described previously (40). The F(ab')2 were repassed over a protein A-Sepharose 4B column (Pharmacia) to remove Fc fragments and undigested IgG. Confluent quiescent layers of HUVEC were incubated with increasing concentrations of F(ab')2 anti-CaR, F(ab')2 anti-SRBC, or BSA for 1 h at 4°C; washed; and then incubated with 50 µg/ml C1q or BSA. After 48-h incubation, supernatants were tested in ELISA for IL-6, IL-8, and MCP-1 concentrations. All incubations were performed in medium 199 containing 0.5% FCS.

Analysis of mRNA production by HUVEC after stimulation with C1q

Confluent quiescent layers of HUVEC were incubated in T25 flasks (Greiner, Alphen a/d Rijn, The Netherlands) for 24 h with either medium alone (medium 199 containing 0.5% FCS) or with medium containing 50 µg/ml C1q. Cells were then detached by trypsin treatment, and total RNA was isolated as described by Chomczynski (41). By reverse transcription, 1 µg of RNA was transcribed into cDNA by oligo(dT) priming (42). Oligonucleotide primers were constructed from known cDNA sequences of IL-6 (43) (sense, 5'-GTACCCCCAGGAGAAGATTC-3'; antisense, 5'-ATTCAGCTCGAACACTTTGA-3'), IL-8 (44) (sense, 5'-GCTTTCTGATGGAAGAGAGC-3'; antisense, 5'-TGTGGATCCTGGCTAGCAGA-3'), MCP-1 (45) (sense, 5'-AACTGAAGCTCGCACTCTCG-3'; antisense, 5'-TCAGCACAGATCTCCTTGGC-3'), and ß-actin (46) (sense, 5'-CTACAATGAGCTGCGTGTGG-3'; antisense, 5'-AAGGAAGGCTGGAAGAGTGC-3'). For the PCR reaction, 10 ml of cDNA, 50 pmol of sense primer, 50 pmol of antisense primer, 1 U of AmpliTaq DNA polymerase (Perkin-Elmer/Cetus, Norwalk, CT), and PCR buffer containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 2.0 mM MgCl2, 2 mg/ml BSA, and 0.25 mM of each dNTP in a total volume of 40 ml were used. The mixture was heated for 5 min at 95°C followed by 33 cycles of 1.5 min at 95°C, 2.5 min at 55°C, 1.5 min at 72°C, and finished by 10 min at 72°C. Ten milliliters of PCR product was separated by electrophoresis on a 1% agarose gel.

MCP-1, IL-6, and IL-8 sandwich ELISAs

Ninety-six-well microtiter plates (MaxiSorb F96, Nunc (Roskilde, Denmark) or Greiner) were coated with monoclonal anti-human MCP-1 Ab (R&D Systems, Abington, U.K.), anti-human IL-6 (5E1, provided by Dr. W. Buurman, University Hospital Maastricht, Maastricht, The Netherlands), or anti-IL-8 mAb (CLB, Amsterdam, The Netherlands) and subsequently blocked with PBS containing 0.01% Tween and 2% casein. After washing, appropriate dilutions of samples were added, incubated for 1 h at 37°C, washed, and then incubated with a rabbit polyclonal anti-MCP-1 (created in our laboratory by immunization of a rabbit with recombinant human MCP-1 (PeproTech, Rocky Hill, NJ)) (47), anti-IL-6 (created in our laboratory by immunization of a rabbit with recombinant human IL-6 (Sandoz, Hanover, NJ)), or anti-IL-8 (created in our laboratory using rIL-8 (PeproTech)) for 1 h at 37°C. Finally, the wells were incubated with horseradish peroxidase (HRP)-conjugated polyclonal IgG (Jackson ImmunoResearch Laboratories, West Grove, PA). After addition of the substrate for HRP, 2,2'-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma), the OD was measured at 415 nm, and the cytokine concentration was calculated relative to a MCP-1, IL-6, or IL-8 standard.

Factor H ELISA

For the measurement of factor H, 96-well titer plates (Greiner) were coated for 2 h at 37°C with affinity-purified polyclonal anti-factor H. Appropriately diluted supernatants were added after washing, incubated for 1 h at 37°C, and then washed and incubated for 1 h at 37°C with digoxigenin-conjugated affinity-purified rabbit anti-human factor H polyclonal Ab. Finally, after washing the wells were incubated with HRP-conjugated sheep F(ab')2 anti-digoxigenin (Boehringer Mannheim, Mannheim, Germany) and developed with 2,2'-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid). OD was measured at 415 nm, and the concentration of factor H was calculated relative to known concentrations of factor H in pooled normal human serum.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
To determine the effect of C1q on the ability of HUVEC to produce IL-6, IL-8, and MCP-1 under basal conditions, quiescent confluent layers of HUVEC were incubated for 48 h at 37°C with increasing concentrations of C1q or BSA. Supernatants were harvested and tested in ELISA in appropriate dilutions. Basal levels of IL-8 (82 ± 91 pg/ml), IL-6 (79 ± 113 pg/ml), and MCP-1 (503 ± 221 pg/ml) were detected. However, supernatants of cells that were stimulated with increasing concentrations of C1q showed a dose-dependent production of IL-6 (maximum, 392 ± 20 pg/ml), IL-8 (maximum, 1012 ± 43 pg/ml), and MCP-1 (maximum, 2450 ± 101 pg/ml; Fig. 1GoA). As an example of the dose-dependent and saturable production of the different peptides, the data for IL-8 are shown in Fig. 1GoB. As a control, the concentration of factor H was assessed. Although Berger et al. (48) described factor H production by HUVEC after stimulation with IFN-{gamma}, and Brooimans et al. (49) described regulation of factor H production by T cell growth factor and IFN-{gamma}, no significant up-regulation of factor H was observed after stimulation with C1q.



View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 1. Dose-dependent production of IL-6, IL-8, and MCP-1 by HUVEC after incubation with increasing concentrations of C1q. Confluent layers of HUVEC were rendered quiescent by overnight incubation with medium containing 0.5% FCS and were then incubated for 48 h with medium containing increasing amounts of C1q (dashed bars) or BSA (open bars). Supernatants were tested with specific ELISAs for the presence of IL-6, IL-8, MCP-1, and factor H (A). As an example, the production of IL-8 in the presence of C1q (l) or BSA (n) at different doses is shown (B). The mean production ± SD is shown for experiments in triplicate cultures.

 
Based on these experiments, a concentration of 100 µg/ml C1q was chosen as the optimal dose for stimulation of HUVEC. Following incubation of HUVEC with this concentration of C1q, the kinetics of cytokine and chemokine production were investigated. Quiescent confluent layers of HUVEC were stimulated with C1q or BSA, and supernatants were obtained at different time points. Measurements of the different peptides under study revealed a time-dependent production of all factors, with a maximum at 48 h of 501 ± 112 pg/ml of IL-6, 1019 ± 52 pg/ml of IL-8, and 2133 ± 104 pg/ml of MCP-1. No significant production was detected after incubation with BSA. As an example of the response, the data for IL-8 production are shown in Fig. 2Go.



View larger version (11K):
[in this window]
[in a new window]
  		FIGURE 2. Time-dependent production of IL-8 by HUVEC after incubation with C1q. Quiescent layers of HUVEC were incubated with 100 µg/ml C1q (l) or BSA (n) for different lengths of time. Using a specific ELISA, the concentration of IL-8 was measured in the supernatants. The mean production ± SD is shown for experiments in triplicate cultures.

 
Since C1q is known to interact with IgG- and IgM-containing immune complexes (40, 50), we assessed the effect of AIgM on HUVEC preloaded with C1q. HUVEC were preincubated with a suboptimal concentration of C1q and after washing were incubated with increasing concentrations of human AIgM. After culture, supernatants were tested for IL-6, IL-8, and MCP-1. Because the response was comparable for all peptides under study, only data for IL-8 production are shown (Fig. 3Go). Addition of AIgM enhanced the production of all peptides compared with stimulation with C1q alone. Whereas C1q alone resulted in a maximal production of 395 ± 33 pg/ml of IL-6, 500 ± 180 pg/ml of IL-8, and 1702 ± 447 pg/ml of MCP-1, addition of AIgM enhanced the maximal production to 997 ± 21 pg/ml of IL-6, 2500 ± 422 pg/ml of IL-8, and 5343 ± 302 pg/ml of MCP-1. Incubation of HUVEC with AIgM alone did not affect the production of IL-6, IL-8, or MCP-1.



View larger version (11K):
[in this window]
[in a new window]
  		FIGURE 3. Surface aggregation of C1q on HUVEC by AIgM enhances IL-8 production. Confluent layers of HUVEC were preincubated with 50 µg/ml C1q (l) or BSA (n), washed, and then incubated with increasing concentrations of AIgM. After 48 h of incubation at 37°C, the supernatants were removed and were tested by specific ELISA for the presence of IL-8. The mean production ± SD is shown forexperiments in triplicate cultures.

 
To determine whether the effect of C1q was mediated via its collagen-like stalks or globular heads, HUVEC were incubated with C1q in the presence or the absence of the C1q fragments or BSA. Incubation with intact C1q alone resulted in the production of 290 ± 21 pg/ml of IL-8, 111 ± 11 pg/ml of IL-6, and 714 ± 31 pg/ml of MCP-1. Since the inhibitions of peptides due to coincubation with the different C1q fragments were very similar, Fig. 4Go only depicts the percent inhibition of IL-8 production. It was found that the presence of the collagen-like stalks of C1q resulted in 69 ± 7% inhibition of IL-8 production. Globular heads of C1q were only able to inhibit C1q-mediated production to a limited extent (13 ± 11%), whereas BSA had no significant effect (3 ± 2%).



View larger version (35K):
[in this window]
[in a new window]
  		FIGURE 4. Inhibition of C1q-mediated IL-8 production by coincubation with C1q collagen-like stalks. Confluent layers of HUVEC were rendered quiescent and incubated for 48 h with C1q in the presence or the absence of C1q collagen-like stalks, C1q globular heads, or BSA. The percent inhibition of the production of IL-8 was calculated and depicted. The mean production ± SD is shown for experiments in triplicate cultures.

 
To determine whether the observed production of IL-6, IL-8, and MCP-1 was de novo, HUVEC were incubated with C1q in the presence or the absence of cycloheximide. The concentrations of IL-6, IL-8, and MCP-1 were determined and are depicted in Fig. 5Go. Cycloheximide was able to significantly inhibit C1q-induced production of all peptides. The production of factor H was studied as a control and was shown to be reduced nonsignificantly in the presence of cycloheximide.



View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 5. IL-6, IL-8, and MCP-1 production by HUVEC in the presence of cycloheximide. HUVEC were preincubated with 10 µg/ml cycloheximide, washed, and then incubated in the presence (closed bars) or the absence (dashed bars) of the same concentration of cycloheximide together with 100 µg/ml C1q. The open bars represent cells that were not stimulated by C1q. After 48 h, supernatants were harvested and assessed for IL-6, IL-8, and MCP-1 by ELISA. As a control the concentration of factor H was determined. The mean production ± SD is shown for experiments in triplicate cultures.

 
Also, de novo production of IL-6, IL-8, and MCP-1 was analyzed by detection of specific mRNA products. Therefore, total RNA, isolated from HUVEC that were incubated with either medium or C1q, was reverse transcribed into cDNA by random priming. Using specific primers for IL-6, IL-8, MCP-1, and ß-actin, cDNA was amplified by PCR, an aliquot was electrophoresed on an agarose gel, and the specific bands with correct base pair lengths were analyzed. Fig. 6Go demonstrates a basal level of specific mRNA for IL-6, IL-8, and MCP-1. Significant up-regulation of specific mRNA was found after stimulation with C1q for all peptides. As a control for equal loading the intensity of ß-actin is shown.



View larger version (88K):
[in this window]
[in a new window]
  		FIGURE 6. Specific cytokine and chemokine mRNA up-regulation after stimulation of HUVEC by C1q. RT-PCR was performed on RNA isolated from confluent layers of HUVEC that were stimulated for 24 h with medium or 50 µg/ml C1q using specific primers for IL-6, IL-8, MCP-1, and ß-actin. An aliquot of the PCR product was analyzed by agarose gel electrophoresis. Bands of the expected weights are shown.

 
To determine the involvement of cC1qR/CaR in the production of IL-8, IL-6, and MCP-1, inhibition experiments were performed in which HUVEC were preincubated with F(ab')2 anti-CaR or an irrelevant F(ab')2 Ab followed by incubation with C1q. Next, the concentrations of IL-8 were determined, and the inhibitory effect of F(ab')2 anti-CaR was calculated (Fig. 7Go). Stimulation of HUVEC with 50 µg/ml of C1q alone resulted in the production of 320 ± 22 pg/ml IL-8. Preincubation of HUVEC with increasing concentrations of F(ab')2 anti-CaR demonstrated a dose-dependent inhibition of IL-8 production with a maximum of 70 ± 8%. Irrelevant F(ab')2 Ab only induced a maximum of 13% inhibition.



View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 7. Inhibition of C1q-induced IL-8 production by preincubation of HUVEC with F(ab')2 anti-calreticulin. Quiescent layers of HUVEC were incubated for 1 h with increasing concentrations of either rabbit F(ab')2 anti-calreticulin or F(ab')2 anti-SRBC. After washing, the cells were incubated in medium containing 50 µg/ml C1q or BSA for another 48 h. Subsequently, the concentrations of IL-8 in the supernatants were measured and expressed as the percent inhibition of IL-8 production.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The present study, to our knowledge for the first time, demonstrates that interaction of C1q with EC in culture results in enhanced, de novo production of IL-8, IL-6, and MCP-1 and not of factor H. This effect was both time and dose dependent.

As we have shown previously, binding of monomeric C1q to cell surface C1qR is far less efficient than binding of multimeric C1q. Therefore, the described results are probably mediated via binding of aggregated C1q, present in the C1q preparation, to cC1qR/CaR (31, 51). The observed cytokine and chemokine production might be effected by cross-linking of cC1qR/CaR by these multimeric C1q molecules. This hypothesis is supported by the observation that enhanced cross-linking of the receptor by subsequent incubation with aggregated IgM resulted in further up-regulation of all factors studied.

Cross-linking of cC1qR/CaR by C1q seems to be a prerequisite for the different effects that are described to be mediated via C1q binding. However, until now no clear consensus exists concerning the underlying second messenger system. One study indicated that the concentrations of the second messenger inositol 1,4,5-trisphosphate were clearly up-regulated after stimulation of cC1qR/CaR on platelets by C1q (52), whereas a recent study by Leigh et al. (53) demonstrated the involvement of G protein-coupled signal transduction mechanisms in C1q-mediated chemotaxis of neutrophils.

The results indicate that the effect of C1q on EC is exerted via the collagen-like stalk of C1q. EC have been described to express three types of C1q binding proteins, namely gC1qR, cC1qR/CaR, and C1qRp. gC1qR, a 33-kDa glycoprotein present on EC and on some other cells, was initially described as a membrane receptor interacting with C1q globular heads, but also with vitronectin and kininogen (54, 55). More recently, however, our own studies and those of others have demonstrated that gC1qR is a mitochondrial protein (26, 27, 28, 56). The absence of a membrane-spanning domain in the cloned gC1qR is consistent with this finding. Even when gC1qR is present on EC membranes, the inhibition experiments with the C1q collagen-like stalks and C1q globular heads in this study suggest that a minimal contribution of the globular heads mediated cytokine and chemokine production.

The other two C1q binding proteins, cC1qR/CaR and C1qRp, are more likely to be involved in C1q-mediated triggering of EC, because both these receptors are present on EC. Moreover, the interaction between cC1qR/Ca and C1q has been demonstrated, whereas such an interaction between C1qRp and C1q is suggested by experiments demonstrating that Abs against C1qRp are able to block C1q-mediated enhancement of phagocytosis by monocytes. CC1qR/CaR, a 60-kDa glycoprotein, is present on almost every cell type studied, including EC (3, 19, 24, 57, 58, 59, 60, 61, 62, 63, 64). It binds to the collagen-like stalks of C1q and has been shown to mediate, for example, C1q-induced platelet aggregation (65). The recently cloned and sequenced 126-kDa C1qRp, with high levels of expression on myeloid and EC, has been shown to be involved in C1q-mediated enhancement of monocyte phagocytosis (16, 23, 25).

In the present study we were able to show that F(ab')2 anti-CaR inhibits IL-8 production by 70% after stimulation of HUVEC with C1q. This experiment indicates the involvement of cC1qR/CaR in the above described effects. However, because production of IL-8 was not fully inhibitable by F(ab')2 anti-CaR, other C1q binding molecules in the membrane may be involved.

Until now, only two functions were described for the different C1q receptors on EC. First, it was shown earlier that binding of C1q to cC1qR/CaR results in a reduction of C1q hemolytic activity (22, 66). Second, binding of C1q to cC1qR/CaR mediates binding of immune complexes, which may lead to increased adhesion of leukocytes or bacteria (16, 51, 67).

As we have shown in the present study, binding of immune complexes might also enhance the C1q-mediated triggering of EC and production of cytokines and chemokines to a great extent. Therefore, we hypothesize that in vivo, binding of immune complexes to EC can result in vascular damage in different ways. First, C1q-containing immune complexes may activate the complement system that might injure autologous cells in the vicinity of the immune complex deposits by formation of a membrane attack complex. Also, chemoattractive cytokines, formed during the complement cascade, may attract inflammatory cells. Second, C1q-containing immune complexes may induce cross-linking of cC1qR/CaR on the cell surface. As shown in this study, this may greatly enhance the production of IL-6, IL-8, and MCP-1. In general, IL-6 will act as a proinflammatory molecule because it is able to stimulate the growth and differentiation of B cells and T cells (68, 69), it is capable of inducing synthesis of acute phase proteins by hepatocytes (70, 71), and it enhances leukocyte adherence to EC (72). However, IL-6 can also be viewed as an anti-inflammatory cytokine, since it inhibits TNF production by monocytes (73, 74) and induces the release of IL-1R antagonist and soluble TNF receptor in the liver, which are inhibitors of IL-1 and TNF, respectively (75, 76).

Attraction of inflammatory cells, on the other hand, is predominantly mediated by IL-8 and MCP-1, which belong to different subfamilies of structurally homologous cytokines, entitled the {alpha}, ß, and C subfamilies of chemokines (77, 78). Members of the {alpha} subfamily, such as IL-8, are chemotactic for neutrophils (79), whereas members of the ß subfamily, such as MCP-1, macrophage inflammatory protin-1{alpha}, and RANTES, are chemotactic for monocytes and lymphocytes (80).

Next to chemoattraction, IL-8 may also enhance adherence of neutrophils to endothelium by increasing ß2 integrin expression and regulation of trans-endothelial migration of neutrophils (81).

In addition to the C1q stimulus, IL-6, IL-8, and MCP-1 are known to be produced in response to autocrine stimulation of EC with IL-1 and TNF. Stimulation with IL-1 and TNF, however, results in a number of responses, including enhancement of permeability (82); expression of adhesion molecules such as ICAM-1, ELAM, and VCAM-1 (83, 84); production of hemopoietic growth factors, IL-1, IL-6, leukemia inhibitory factor, IL-8, platelet-derived growth factor, MCP-1, RANTES, platelet-activating factor, and the PGs PFE2 and PGI2 (84, 85, 86, 87). Many of these factors can subsequently activate other cells or have an effect on EC itself. Therefore, we hypothesize that the reaction of EC to stimulation with C1q is probably not limited to IL-6, IL-8, and MCP-1, but may also involve, for example, adhesion molecules or molecules with procoagulant activity. Subsequently, lymphocytes, neutrophils, and monocytes may be attracted by IL-8 and MCP-1, respectively, whereas IL-6 and IL-8 may enhance the adherence of these cells to EC (72, 81). These mechanisms therefore may amplify an ongoing inflammatory response, leading to tissue injury.


   Footnotes
 
1 This work was supported by The Netherlands Organization for Scientific Research, EC-BioTech BIO4-CT97-2242, and was performed in the context of the EU-BioMed-2 program: Role of Complement in Susceptibility to Infectious and Chronic Diseases (BMH4-CT96-1005). Back

2 Address correspondence and reprint requests to Dr. M. R. Daha, Department of Nephrology, Building 1, D3-P, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands. E-mail address: Back

3 Abbreviations used in this paper: EC, endothelial cells; C1qR, receptor for the subcomponent of the first component of complement C1; gC1qR, receptor for globular domain of C1q; CC1qR/CaR, receptor for collagen-like stalk of C1q with calreticulin identity; C1qRp, receptor for C1q that mediates phagocytosis; MCP-1, monocyte chemotactic peptide-1; AigM, aggregated rabbit immunoglobulin M; CaR, calreticulin receptor; HRP, horseradish peroxidase. Back

Received for publication December 22, 1997. Accepted for publication August 27, 1998.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Andrews, B. S., M. Shadforth, P. Cunningham, IV J. S. Davis. 1981. Demonstration of a C1q receptor on the surface of human endothelial cells. J. Immunol. 127:1075.[Abstract]
  2. Linder, E.. 1981. Binding of C1q and complement activation by vascular endothelium. J. Immunol. 126:648.[Abstract]
  3. Peerschke, E. I. B., R. Malhotra, B. Ghebrehiwet, K. B. M. Reid, A. C. Willis, R. B. Sim. 1993. Isolation of a human endothelial cell C1q receptor (C1qR). J. Leukocyte Biol. 53:179.[Abstract]
  4. Bordin, S., W. P. Kolb, R. C. Page. 1983. C1q receptors on cultured human gingival fibroblasts: analysis of binding properties. J. Immunol. 130:1871.[Abstract]
  5. Bordin, S., M. Smith, B. Ghebrehiwet, D. Oda, R. C. Page. 1992. Smooth muscle and epithelial cells express specific binding sites for the C1q component of complement. Clin. Immunol. Immunopathol. 63:51.[Medline]
  6. Peerschke, E. I. B., B. Ghebrehiwet. 1987. Human blood platelets possess specific binding sites for C1q. J. Immunol. 138:1537.[Abstract]
  7. Young, K. R., J. L. Ambrus, A. Malbran, A. S. Fauci, A. J. Tenner. 1991. Complement subcomponent C1q stimulates immunoglobulin production by human B lymphocytes. J. Immunol. 146:3356.[Abstract]
  8. Hamada, A., B. M. Greene. 1987. C1q enhancement of IgG-dependent eosinophil-mediated killing of Schistosomula in vitro. J. Immunol. 138:1240.[Abstract/Free Full Text]
  9. Bobak, D. A., M. M. Frank, A. J. Tenner. 1986. Characterization of C1q receptor expression on human phagocytic cells: effects on PDBu and fMLP. J. Immunol. 136:4604.[Abstract]
  10. Bobak, D. A., T. G. Gaither, M. M. Frank, A. J. Tenner. 1988. Modulation of FcR function by complement subcomponent C1q enhances the phagocytosis of IgG-opsonized targets by human monocytes and culture-derived macrophages. J. Immunol. 138:1150.[Abstract/Free Full Text]
  11. Bobak, D. A., M. M. Frank, A. J. Tenner. 1988. C1q acts synergistically with phorbol dibutyrate to activate CR1-mediated phagocytosis by human mononuclear phagocytes. Eur. J. Immunol. 18:2001.[Medline]
  12. Sorvillo, J. M., I. Gigli, E. Pearlstein. 1986. The effect of fibronectin on the processing of C1q- and C3b/bi-coated immune complexes by peripheral blood monocytes. J. Immunol. 136:1023.[Abstract]
  13. Tenner, A. J., R. Young, A. Malbran, A. S. Fauci, Jr J. L. Ambrus. 1987. In vitro modulation of B cell immunoglobulin (Ig) synthesis by the C1q subcomponent of complement. Fed. Proc. 46:1195.
  14. Tenner, A. J., N. R. Cooper. 1982. Stimulation of a human polymorphonuclear leukocyte oxidative response by the C1q subunit of the first complement component. J. Immunol. 128:2547.[Medline]
  15. Ryan, U. S., J. D. Goodwin, J. M. Vann, D. R. Schultz. 1981. Effect of C1q on phagocytosis of Salmonella minnesota by endothelium. Complement 4:220.
  16. Lozada, C., R. I. Levin, M. Huie, R. Hirschhorn, D. Naime, M. Whitlow, P. A. Recht, B. Golden, B. N. Cronstein. 1995. Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc. Natl. Acad. Sci. USA 92:8378.[Abstract/Free Full Text]
  17. Ghebrehiwet, B., B.-L. Lim, E. I. B. Peerschke, A. C. Willis, K. B. M. Reid. 1994. Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q. J. Exp. Med. 179:1809.[Abstract/Free Full Text]
  18. Eggleton, P., B. Ghebrehiwet, K. N. Sastry, J. Coburn, K. S. Zaner, K. B. M. Reid, A. I. Tauber. 1995. Identification of a gC1q-binding protein (gC1q-R) on the surface of human neutrophils. J. Clin. Invest. 95:1569.
  19. Malhotra, R., A. C. Willis, J. C. Jensenius, J. Jackson, R. B. Sim. 1993. Structure and homology of human C1q receptor (collectin receptor). Immunology 78:341.[Medline]
  20. Eggleton, P., T. S. Lieu, E. G. Zappi, K. Sastry, J. Coburn, K. S. Zaner, R. D. Sontheimer, J. D. Capra, B. Ghebrehiwet, A. I. Tauber. 1994. Calreticulin is released from activated neutrophils and binds to C1q and mannan-binding protein. Clin. Immunol. Immunopathol. 72:405.[Medline]
  21. Jonsson, H., G. Sturfelt. 1990. A novel assay for neutrophil clustering activity of human sera: relation to disease activity and neutropenia in systemic lupus erythematosus. Ann. Rheum. Dis. 49:46.[Abstract/Free Full Text]
  22. Daha, M. R., L. Dunn, R. H. van den Berg, Y. Muizert-de Lange, A. F. Gerritsen, L. A. van Es. 1993. Isolation of a human endothelial cell C1q receptor. Mediat. Inflamm. 2:447.
  23. Guan, E., S. L. Robinson, E. B. Goodman, A. J. Tenner. 1994. Cell-surface protein identified on phagocytic cells modulates the C1q-mediated enhancement of phagocytosis. J. Immunol. 152:4005.[Abstract]
  24. Ghebrehiwet, B., R. R. Kew, B. L. Gruber, M. J. Marchese, E. I. B. Peerschke, K. B. M. Reid. 1995. Murine mast cells express two types of C1q receptor that are involved in the induction of chemotaxis and chemokinesis. J. Immunol. 155:2614.[Abstract]
  25. Nepomuceno, R. R., A. H. Henschen-Edman, W. H. Burgess, A. J. Tenner. 1997. cDNA cloning and primary structure analysis of C1qR(P), the human C1q/MBL/SPA receptor that mediates enhanced phagocytosis in vitro. Immunity 6:119.[Medline]
  26. Herwald, H., J. Dedio, R. Kellner, M. Loos, W. Muller-Esterl. 1996. Isolation and characterization of the kininogen-binding protein P33 from endothelial cells: identity with the gC1qR receptor. J. Biol. Chem. 271:13040.[Abstract/Free Full Text]
  27. van den Berg, R. H., F. Prins, M. C. Faber-Krol, N. J. Lynch, W. Schwaeble, L. A. van Es, M. R. Daha. 1997. Intracellular localization of the human receptor for the globular domains of C1q. J. Immunol. 158:3909.[Abstract]
  28. Dedio, J., W. Jahnen-Dechent, M. Bachmann, W. Muller-Esterl. 1998. The multiligand-binding protein gC1qR, putative C1q receptor, is a mitochondrial protein. J. Immunol. 160:3534.[Abstract/Free Full Text]
  29. Wing, M. G., D. J. Seilly, D. J. Bridgman, R. A. Harrison. 1993. Rapid isolation and biochemical characterization of rat C1 and C1q. Mol. Immunol. 30:433.[Medline]
  30. Kolb, W. P., L. M. Kolb, E. R. Podack. 1979. C1q: isolation from human serum in high yield by affinity chromatography and development of a highly sensitive hemolytic assay. J. Immunol. 122:2103.[Abstract/Free Full Text]
  31. Daha, M. R., N. Klar, R. Hoekzema, L. A. van Es. 1990. Enhanced IgG production by human peripheral lymphocytes induced by aggregated C1q. J. Immunol. 144:12.
  32. Siegel, R. C., V. N. Schumacher. 1983. Measurement of the association constants of the complement formed between intact C1q or pepsin-treated C1q stalks and the unactivated or activated C1r2C1s2 tetrameres. Mol. Immunol. 20:53.[Medline]
  33. Hoekzema, R., M. Martens, M. C. Brouwer, L. E. Hack. 1988. The distortive mechanism for the activation of complement component C1, supported by studies with a monoclonal antibody against the "arms" of C1q. Mol. Immunol. 25:485.[Medline]
  34. Jaffe, E. A., R. L. Nachman, C. G. Becker, C. R. Minick. 1981. Culture of human endothelial cells derived from umbilical veins. J. Clin. Invest. 52:2745.
  35. Maciag, T., J. Cerundolo, J. Isley, P. R. Kelley, F. Forand. 1979. An endothelial growth factor from bovine hypothalamus: identification and partial characterization. Proc. Acad. Natl. Sci. USA 76:5674.[Abstract/Free Full Text]
  36. Berger, S. P., M. A. Seelen, P. S. Hiemstra, J. S. Gerritsma, E. Heemskerk, F. J. van der Woude, M. R. Daha. 1996. Proteinase 3, the major autoantigen of Wegener’s granulomatosis, enhances IL-8 production by endothelial cells in vitro. J. Am. Soc. Nephrol. 7:694.[Abstract]
  37. Kijlstra, A., A. van der Lelij, W. Knutson, G. J. Fleuren, L. A. van Es. 1978. The influence of phagocyte function on glomerular localization of aggregated IgM in rats. Clin. Exp. Immunol. 32:207.[Medline]
  38. Malhotra, R., A. C. Willis, A. Lopez Bernal, S. Thiel, R. B. Sim. 1994. Mannan-binding protein levels in human amniotic fluid during gestation and its interaction with collectin receptor from amnion cells. Immunology 82:439.[Medline]
  39. Crockard, A. D., J. M. Thompson, R. Malhotra, T. A. McNeill. 1993. Increased expression of C1q receptors on neutrophils from inflammatory joint fluids. Immunol. Lett. 36:195.[Medline]
  40. Kijlstra, A., L. A. van Es, M. R. Daha. 1979. Enhanced degradation of soluble immunoglobulin aggregates by macrophages in the presence of complement. Immunology 37:673.[Medline]
  41. Chomczynski, P., N. Sacchi. 1987. Single step method of isolation by acid quanidinium thioglycanate-phenol-chloroform extraction. Anal. Biochem. 162:156.[Medline]
  42. van den Dobbelsteen, M. E. A., V. Verhasselt, J. G. J. Kaashoek. 1994. Regulation of C3 and factor H synthesis of human glomerular mesangial cells by interleukin 1 and interferon-{gamma}. Clin. Exp. Immunol. 95:173.[Medline]
  43. Wong, G. G., G. Witek-Giannotti, R. M. Hewick, S. C. Clark, M. Ogawa. 1988. Interleukin 6: identification as a hematopoietic colony stimulating factor. Behring Inst. Mitt. 83:40.
  44. Hotta, K., K. Havashi, J. Ishikawa, M. Tagawa, K. Hashimoto, S. Hizumo, K. Suzuki. 1990. Coding region structure of interleukin-8 gene of human lung giant cell carcinoma LU65C cells that produce LUCT/interleukin-8: homogeneity in interleukin-8 genes. Immunol. Lett. 24:165.[Medline]
  45. Rollins, B. J., P. Stier, T. Ernst. 1989. The human homolog of the JE gene encodes a monocyte secretory protein. Mol. Cell. Biol. 9:4687.[Abstract/Free Full Text]
  46. Ponte, P., N. Engel, P. Gunning. 1984. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human ß-actin cDNA. Nucleic Acids Res. 12:1687.[Abstract/Free Full Text]
  47. Prodjosudjadi, W., J. S. J. Gerritsma, L. A. van Es, M. R. Daha, J. A. Bruijn. 1995. Monocyte chemoattractant protein-1 in normal and diseased human kidneys: an immunohistochemical analysis. Clin. Nephrol. 44:148.[Medline]
  48. Dauchel, H., N. Julen, C. Lemercier, M. Daveau, D. Ozanne, M. Fontaine, J. Ripoche. 1990. Expression of complement alternative pathway proteins by endothelial cells: differential regulation by interleukin 1 and glucocorticoids. Eur. J. Immunol. 20:1669.[Medline]
  49. Brooimans, R. A., P. S. Hiemstra, A. A. van der Ark, R. B. Sim, L. A. van Es, M. R. Daha. 1989. Biosynthesis of complement factor H by human umbilical vein endothelial cells: regulation by T cell growth factor and IFN-gamma. J. Immunol. 142:2024.[Abstract]
  50. Coremans, I. E. M., W. M. J. M. Bogers, R. K. Stad, E. A. M. van der Voort, F. A. Prins, N. van Rooijen, F. C. Breedveld, M. R. Daha. 1993. Role of liver endothelial and Kupffer cells in clearance of human C1q in rats. Eur. J. Immunol. 23:1942.[Medline]
  51. Daha, M. R., A. M. M. Miltenburg, P. S. Hiemstra, N. Klar-Mohamad, L. A. van Es, V. W. M. van Hinsbergh. 1988. The complement subcomponent C1q mediates binding of immune complexes and aggregates to endothelial cells in vitro. Eur. J. Immunol. 18:783.[Medline]
  52. Ghebrehiwet, B., P. D. Lu, W. Zhang, S. A. Keilbaugh, L. E. A. Leigh, P. Eggleton, K. B. M. Reid, E. I. B. Peerschke. 1997. Evidence that the two C1q binding membrane proteins, gC1qR and cC1qR, associate to form a complex. J. Immunol. 159:1429.[Abstract]
  53. Leigh, L. E., B. Ghebrehiwet, T. P. Perera, I. N. Bird, P. Strong, U. Kishore, K. B. Reid, P. Eggleton. 1998. C1q-mediated chemotaxis by human neutrophils: involvement of gC1qR and G-protein signalling mechanisms. Biochem. J. 330:247.
  54. Dedio, J., W. Muller-Esterl. 1996. Kininogen binding protein p33/gC1qR is localized in the vesicular fraction of endothelial cells. FEBS Lett. 399:255.[Medline]
  55. Lim, B. L., K. B. M. Reid, B. Ghebrehiwet, E. I. B. Peerschke, L. A. E. Leigh, K. T. Preissner. 1996. The binding protein for globular heads of complement C1q, gC1qR. J. Biol. Chem. 271:26739.[Abstract/Free Full Text]
  56. Peerschke, E. I. B., K. B. M. Reid, B. Ghebrehiwet. 1994. Identification of a novel 33-kDa C1q-binding site on human blood platelets. J. Immunol. 152:5896.[Abstract]
  57. Dedhar, S.. 1994. Novel functions for calreticulin: interaction with integrins and modulation of gene expression?. Trends Biochem. Sci. 19:269.[Medline]
  58. Wada, I., S. Imai, M. Kai, F. Sakane, H. Kanoh. 1995. Chaperone function of calreticulin when expressed in the endoplasmic reticulum as the membrane-anchored forms. J. Biol. Chem. 270:20298.[Abstract/Free Full Text]
  59. Ghebrehiwet, B., L. Silvestri, C. McDevitt. 1984. Identification of the Raji cell membrane-derived C1q inhibitor as a receptor for human C1q. J. Exp. Med. 160:1375.[Abstract/Free Full Text]
  60. Ghebrehiwet, B., S. Bossone, A. Erdei, K. B. M. Reid. 1988. Reversible biotinylation of C1q with a cleavable biotinyl derivative. J. Immunol. Methods 110:251.[Medline]
  61. Malhotra, R., R. B. Sim. 1989. Chemical and hydrodynamic characterization of the human leucocyte receptor for complement subcomponent C1q. Biochem. J. 262:625.[Medline]
  62. Chen, A., S. Gaddipati, Y. Hong, D. J. Volkman, E. I. B. Peerschke, B. Ghebrehiwet. 1994. Human T cells express specific binding sites for C1q. J. Immunol. 153:1430.[Abstract]
  63. D’Cruz, O. J., C. A. Toth, G. G. Haas. 1996. Recombinant soluble human complement receptor type 1 inhibits antisperm antibody- and neutrophil-mediated injury to human sperm. Biol. Reprod. 54:1217.[Abstract]
  64. Bordin, S., B. Ghebrehiwet, R. C. Page. 1990. Participation of C1q and its receptor in adherence of human diploid fibroblast. J. Immunol. 145:2520.[Abstract]
  65. Peerschke, E. I. B., K. B. M. Reid, B. Ghebrehiwet. 1993. Platelet activation by C1q results in the induction of ?IIb/?3 integrins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity. J. Exp. Med. 178:579.[Abstract/Free Full Text]
  66. van den Berg, R. H., M. C. Faber-Krol, L. A. van Es, M. R. Daha. 1995. Regulation of the function of the first component of complement by human C1q receptor. Eur. J. Immunol. 25:2206.[Medline]
  67. Ryan, U. S., D. R. Schultz, J. D. Goodwin, J. M. Vann, M. P. Selvaraj, M. A. Hart. 1989. Role of C1q in phagocytosis of Salmonella minnesota by pulmonary endothelial cells. Infect. Immun. 57:1356.[Abstract/Free Full Text]
  68. Helle, M., L. Boeije, L. A. Aarden. 1989. Interleukin-6 is an intermediate in interleukin-1 induced thymocyte proliferation. J. Immunol. 142:4335.[Abstract]
  69. Helle, M., J. P. J. Brakenhoff, E. R. de Groot, L. A. Aarden. 1988. Interleukin-6 is involved in interleukin-1-induced activities. Eur. J. Immunol. 18:957.[Medline]
  70. Gauldie, J., C. Richards, D. Harnish, P. M. Lansdorp, H. Baumann. 1987. Interferon {gamma}2/B-cell stimulatory factor type-2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute-phase protein response in liver cells. Proc. Natl. Acad. Sci. USA 84:7251.[Abstract/Free Full Text]
  71. Fey, G. H., J. Gauldie. 1990. The acute-phase response of the liver in inflammation. H. Popper, and F. Schaffner, eds. Progress in Liver Disease 89. Saunders, Philadelphia.
  72. Watson, C., S. Whittaker, N. Smith, A. J. Vora, D. C. Dumonde, K. A. Brown. 1996. IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes. Clin. Exp. Immunol. 105:112.[Medline]
  73. Aderka, D., J. Le, J. Vilcek. 1989. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J. Immunol. 143:3517.[Abstract]
  74. Schindler, R., J. Mancilla, S. Endres, R. Ghorbani, S. C. Clark, C. A. Dinarello. 1990. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75:40.[Abstract/Free Full Text]
  75. Tilg, H., E. Trehu, M. B. Atkins, C. A. Dinarello, J. W. Mier. 1994. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83:113.[Abstract/Free Full Text]
  76. Tilg, H., E. Vannier, G. Vachino, C. A. Dinarello, J. W. Mier. 1993. Anti-inflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1-ß synthesis by human peripheral blood mononuclear cells. J. Exp. Med. 178:1629.[Abstract/Free Full Text]
  77. Furie, M. B., G. J. Randolph. 1995. Chemokines and tissue injury. Am. J. Pathol. 147:1287.
  78. Kennedy, J., G. S. Kelner, S. Kleyensteuber. 1995. Molecular cloning and functional characterization of human lymphotactin. J. Immunol. 155:203.[Abstract]
  79. Taub, D. D., A. R. Lloyd, K. Conlon. 1993. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J. Exp. Med. 177:1809.[Abstract/Free Full Text]
  80. Miller, M. D., M. S. Krangel. 1992. Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit. Rev. Immunol. 12:17.[Medline]
  81. Gimbrone, M. A. J., M. S. Obin, A. F. Brock, E. A. Luis, P. E. Hass, C. A. H’bert, Y. K. Yip, D. W. Leung, D. G. Lowe, W. J. Kohr, et al 1989. Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions. Science 246:1601.[Abstract/Free Full Text]
  82. Koga, S., S. Morris, S. Ogawa, H. Liao, J. P. Bilezikian, G. Chen, W. J. Thompson, T. Ashikaga, J. Brett, D. M. Stern. 1995. TNF modulates endothelial properties by decreasing cAMP. Am. J. Physiol. 268:1104.
  83. Gamble, J. R., J. M. Harlan, S. J. Klebanoff. 1985. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc. Natl. Acad. Sci. USA 82:8667.[Abstract/Free Full Text]
  84. Le, J., J. Vilcek. 1987. Biology of disease: tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab. Invest. 56:234.[Medline]
  85. Marfaing-Koka, A., O. Devergne, G. Gorgone, A. Portier, T. J. Schall, P. Galanaud, D. Emilie. 1995. Regulation of the production of the RANTES chemokine by endothelial cells. J. Immunol. 154:1870.[Abstract]
  86. Strieter, R. M., S. L. Kunkel, H. J. Showell, D. G. Remick, S. H. Phan, P. A. Ward, R. M. Marks. 1989. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-{alpha}, LPS, and IL-1ß. Science 243:1467.[Abstract/Free Full Text]
  87. Sica, A., K. Matsushima, J. van Damme, J. M. Wang, N. Polentarutti, E. Dejana, F. Colotta, A. Mantovani. 1990. IL-1 transcriptionally activates the neutrophil chemotactic factor/IL-8 gene in endothelial cells. Immunology 69:548.[Medline]



This article has been cited by other articles:


Home page
 CirculationHome page
E. Shagdarsuren, K. Bidzhekov, Y. Djalali-Talab, E. A. Liehn, M. Hristov, R. A. Matthijsen, W. A. Buurman, A. Zernecke, and C. Weber
C1-Esterase Inhibitor Protects Against Neointima Formation After Arterial Injury in Atherosclerosis-Prone Mice
Circulation, January 1, 2008; 117(1): 70 - 78.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. Zhang, W. Wright, D. A. Bernlohr, S. W. Cushman, and X. Chen
Alterations of the classic pathway of complement in adipose tissue of obesity and insulin resistance
Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1433 - E1440.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
J. Wehner, C. N. Morrell, T. Reynolds, E. R. Rodriguez, and W. M. Baldwin III
Antibody and Complement in Transplant Vasculopathy
Circ. Res., February 2, 2007; 100(2): 191 - 203.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
M. Oroszlan, E. Herczenik, S. Rugonfalvi-Kiss, A. Roos, A. J Nauta, M. R Daha, I. Gombos, I. Karadi, L. Romics, Z. Prohaszka, et al.
Proinflammatory changes in human umbilical cord vein endothelial cells can be induced neither by native nor by modified CRP
Int. Immunol., June 1, 2006; 18(6): 871 - 878.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. W. L. Groeneveld, M. Oroszlan, R. T. Owens, M. C. Faber-Krol, A. C. Bakker, G. J. Arlaud, D. J. McQuillan, U. Kishore, M. R. Daha, and A. Roos
Interactions of the Extracellular Matrix Proteoglycans Decorin and Biglycan with C1q and Collectins
J. Immunol., October 1, 2005; 175(7): 4715 - 4723.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
D. Cadavid, Y. Bai, D. Dail, M. Hurd, K. Narayan, E. Hodzic, S. W. Barthold, and A. R. Pachner
Infection and Inflammation in Skeletal Muscle from Nonhuman Primates Infected with Different Genospecies of the Lyme Disease Spirochete Borrelia burgdorferi
Infect. Immun., December 1, 2003; 71(12): 7087 - 7098.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. D. Kaplan, S. K. O'Neill, T. Koreny, M. Czipri, and A. Finnegan
Development of Inflammation in Proteoglycan-Induced Arthritis Is Dependent on Fc{gamma}R Regulation of the Cytokine/Chemokine Environment
J. Immunol., November 15, 2002; 169(10): 5851 - 5859.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
X. Feng, M. G. Tonnesen, E. I. B. Peerschke, and B. Ghebrehiwet
Cooperation of C1q Receptors and Integrins in C1q-Mediated Endothelial Cell Adhesion and Spreading
J. Immunol., March 1, 2002; 168(5): 2441 - 2448.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Kjaergaard, L. Peng, P. A. Cohen, J. A. Drazba, A. D. Weinberg, and S. Shu
Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor
J. Immunol., December 1, 2001; 167(11): 6669 - 6677.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. E. J. TAEKEMA-ROELVINK, C. V. KOOTEN, S. V. D. KOOIJ, E. HEEMSKERK, and M. R. DAHA
Proteinase 3 Enhances Endothelial Monocyte Chemoattractant Protein-1 Production and Induces Increased Adhesion of Neutrophils to Endothelial Cells by Upregulating Intercellular Cell Adhesion Molecule-1
J. Am. Soc. Nephrol., May 1, 2001; 12(5): 932 - 940.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
Z. Khalkhali-Ellis, G. A. Bulla, L. S. Schlesinger, D. A. Kirschmann, T. L. Moore, and M. J. C. Hendrix
C1q-Containing Immune Complexes Purified from Sera of Juvenile Rheumatoid Arthritis Patients Mediate IL-8 Production by Human Synoviocytes: Role of C1q Receptors
J. Immunol., October 15, 1999; 163(8): 4612 - 4620.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Goicoechea, A. W. Orr, M. A. Pallero, P. Eggleton, and J. E. Murphy-Ullrich
Thrombospondin Mediates Focal Adhesion Disassembly through Interactions with Cell Surface Calreticulin
J. Biol. Chem., November 10, 2000; 275(46): 36358 - 36368.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van den Berg, R. H.
Right arrow Articles by Daha, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van den Berg, R. H.
Right arrow Articles by Daha, M. R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS